Mizuho Upgrades IDEX Corp (IEX) to Outperform

Mizuho analyst Brett Linzey upgraded IDEX Corp (NYSE: IEX) from Neutral to Outperform with a price target of $280.00 (from $210.00).

The analyst comments: “Upgrade IEX to Outperform (from Neutral) and raise our PT to $280 from $210. Our more constructive view reflects increasing evidence that IDEX’s portfolio repositioning toward higher-growth, less-cyclical markets is beginning to translate into stronger organic growth, improved revenue visibility and attractive incremental margins. At the same time, orders have accelerated meaningfully ahead of sales, with 2Q26 organic total orders +28%, and +47% within Health & Science Technologies (HST), creating a strong setup for conversion through 2H26 and into 2027+. We also see an underappreciated second leg to the thesis from the company’s larger short-cycle portfolio, where demand remains near trough or only in the early stages of recovery (see Exhibit 5). We are raising our 2026E/2027E adj. EPS estimates ~5/9% respectively to $8.84/$9.91.”

For an analyst ratings summary and ratings history on IDEX Corp click here. For more ratings news on IDEX Corp click here.

Shares of IDEX Corp closed at $237.31 yesterday.

You May Also Be Interested In

• BNP Paribas Exane Upgrades Serco Group PLC (SRP:LN) (SECCF) to Outperform
• Deutsche Bank Upgrades Entegris Inc (ENTG) to Buy
• Chicago Atlantic Real Estate Finance (REFI) PT Lowered to $16 at Citizens Post Q2 Results